Venture Capital

Financing structure should follow the company’s stage, capital runway, use of proceeds, valuation expectations, acceptable dilution, governance objectives, investor profile, outstanding securities, and timing. A SAFE, convertible promissory note, or priced preferred-stock financing allocates conversion, repayment, maturity, priority, ownership, and control differently; no instrument is universally preferable. Bridge, extension, tranched, milestone-based, and rolling-closing structures may address particular funding needs, but each can create additional conditions, consent requirements, allocation questions, and inconsistent treatment among investors.

A SAFE may address purchase amount, valuation cap, discount, most-favored-nation treatment, pro rata participation, qualified financing, liquidity event, and dissolution outcomes. Its legal character and consequences depend on the actual terms and applicable law; the label does not make it traditional debt or equity and does not supply interest, maturity, repayment, or guaranteed conversion. Multiple SAFE forms, side letters, participation rights, and capitalization definitions should be modeled together and reconciled with the later priced-round documents rather than reviewed as isolated instruments.

A priced preferred-stock round translates the negotiated term sheet into a coordinated document suite. The certificate of incorporation or charter amendment creates the preferred-stock rights, while the stock purchase agreement addresses representations, covenants, conditions, remedies or indemnity where included, and closing deliverables. Relevant economics may include liquidation preference, participation, dividends, conversion, anti-dilution protection, redemption, pay-to-play provisions, and treatment of the option pool. Pre-money and post-money capitalization and fully diluted ownership assumptions should use the same definitions throughout the transaction.

Financing diligence may cover formation and governance records, capitalization, prior securities issuances, founder equity, options and other awards, SAFEs, notes, warrants, side letters, debt, liens, and existing consent rights. Depending on the business, the review may also address IP ownership, employee and contractor arrangements, material contracts, privacy and data practices, disputes, and regulatory matters. Missing approvals, inconsistent capitalization entries, undocumented promises, expired rights, defective issuances, and assignment or change-of-control restrictions should be identified before they affect authority, pricing, conditions, or closing timing.

Each offer and sale of a SAFE, note, preferred stock, warrant, or other security must be registered or qualify for an available exemption. Depending on the facts, the analysis may involve Section 4(a)(2), Regulation D, Rule 506(b), Rule 506(c), or another pathway. Offerings without general solicitation and offerings using general solicitation can carry different purchaser, verification, communication, and record requirements. Accredited-investor status, participation by non-accredited investors, disclosure, bad-actor disqualification, integration, restricted securities, and antifraud obligations require transaction-specific review.